The ubiquitin-proteasome system (UPS) is the major machinery mediating specific protein
turnover in eukaryotic cells. By ubiquitylating unwanted, damaged, or harmful proteins and …

The development of small-molecule inhibitors or stabilizers of selected protein–protein
interactions (PPIs) of interest holds considerable promise for the development of research …

Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD)
molecules that induce degradation by the ubiquitin-proteasome system (UPS) offer new …

Targeted protein degradation technology has evolved a brand-new therapeutic modality
from an innovative drug discovery perspective. Though the classical PROTACs has …

Targeted protein degradation (TPD) has emerged in the past decade as a major new drug
modality to remove intracellular proteins with bispecific small molecules that recruit the …

Targeted protein degradation (TPD) has emerged as a potentially transformational
therapeutic modality with considerable promise. Molecular glue degraders remodel the …

The ubiquitin/proteasome system is a primary conduit for selective intracellular protein
degradation. Since its discovery over 30 years ago, this highly regulated system continues to …

Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle
challenging protein targets deemed undruggable with traditional small molecule inhibitors …

Heterobifunctional molecules have proven powerful tools to induce ligase-dependent
ubiquitination of target proteins. We describe here a chemical strategy for controlling a …

The therapeutic modality of targeted protein degradation promises to overcome limitations of
traditional pharmacology. Small-molecule degraders recruit disease-causing proteins to E3 …